DEFENCE THERAPEUTICS DTCFF overview

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS 19.08.2024 / 16:00 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM ® HYDROGEL...

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES 13.08.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION...

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM 24.07.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO...

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA 08.07.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I...

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS 01.07.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS Vancouver, BC, Canada, June 28th, 2024 - Defence Therapeutics Inc....

EQS-News: Defence Therapeutics Inc. / Key word(s): Study DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS 25.06.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE Vancouver, BC, Canada, June 25th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel...

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN 17.06.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. _________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM...

Malibu, CA, United States (ABN Newswire) - Join Ellis Martin and Money Talk Radio for a conversation with Dr. Moutih Rafei, Chief Science Officer of Defence Therapeutics Inc. (CNSX:DTC) (FRA:DTC) (OTCMKTS:DTCFF). Defence Therapeutics is a publicly traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens...